Study on clinical efficacy of edaravone and dexborneol combined with butylphthalide sodium chloride injection in the treatment of cerebral infarction and its influence on neurological function and daily living ability
Objective To explore the clinical efficacy of edaravone and dexborneol combined with butylphthalide sodium chloride injection in the treatment of cerebral infarction and its influence on neurological function and daily living ability.Methods 92 patients with cerebral infarction were randomly divided into the control group and the study group,with 46 cases in each group.The control group was treated with butylphthalide sodium chloride injection,while the study group was treated with edaravone and dexborneol in combination with the treatment in the control group.Patients in both groups were compared in terms of levels of inflammatory factors[interleukin-8(IL-8),C-reactive protein(CRP),interleukin-10(IL-10)],serum neurofactors[brain-derived neurotrophic factor(BDNF),neuron-specific enolase(NSE),nerve growth factor(NGF)],as well as the degree of neurological deficits,daily living ability,and therapeutic effect.Results After treatment,compared with(21.32±3.67)ng/ml,(10.22±1.37)ng/L,(10.54±2.18)mg/L in the control group,IL-8 of(13.49±3.58)ng/ml,IL-10 of(8.48±1.09)ng/L,and CRP of(6.41±2.13)mg/L in the study group were lower,and the difference was statistically significant(P<0.05).After treatment,compared with(126.40±11.31)pg/ml,(4.36±1.12)ng/ml,and(36.12±2.16)μg/L in the control group,the study group had a higher NGF of(151.48±13.47)pg/ml and BDNF of(5.69±1.04)ng/ml,and a lower NSE of(22.86±2.67)μg/L,and the difference was statistically significant(P<0.05).After treatment,the study group had a lower National Institutes of Health Stroke Scale(NIHSS)score of(5.41±2.18)points than(10.65±3.22)points in the control group,and a higher activities of daily living(ADL)score of(64.49±3.68)points than(53.48±3.45)points in the control group;the difference was statistically significant(P<0.05).The total effective rate of treatment in the study group was 93.48%,which was significantly higher than 78.26%in the control group,and the difference was statistically significant(P<0.05).Conclusion Edaravone and dexborneol combined with butylphthalide sodium chloride injection shows unique advantages in the treatment of patients with cerebral infarction.This combined treatment regimen has positive therapeutic effects in several aspects such as inflammation level,neurological function and daily living ability.
Edaravone and dexborneolButylphthalide sodium chloride injectionCerebral infarctionClinical efficacyNeurological functionDaily living ability
NETL
NSTL
万方数据
